---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000289"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:26:08.385272+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow

## Summary
- Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.
- Prepared a corporate presentation for use in investor meetings as part of a non-deal roadshow.
- Presentation furnished as Exhibit 99.1 and incorporated by reference.
- CEO Ilan Hadar signed the report on behalf of Silexion Therapeutics Corp.
- Presentation titled 'Silencing Oncogenes at the Level of Gene Expression' for Nasdaq: SLXN.

## SEC filing metadata
- accession: 0001178913-26-000289
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/0001178913-26-000289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/zk2634285.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000289
- JSON: https://secwatch.observer/filing/0001178913-26-000289.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.